Letter: Clinical Trials

12 trials of Letter, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 recruiting, 1 unknown. 12 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable12Completed 10, Recruiting 1, Unknown 1

Follow Letter: new trials by email Literature Review of Letter trials Research Report on Letter

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
I CAN DO Surgical ACP
Letter, AD, PREPARE website - Surgical Advanced Care Planning
Not applicableRecruitingUniversity of California, San Francisco60002025-02-262026-08-11
Mammogram Mail- and Phone-based Interventions
Postcard, Letter, Auto-dialer - Breast Cancer
Not applicableCompletedGeisinger Clinic143862023-05-102024-10-10
Efficacy of Communication Modalities for Promoting Flu Shots
Letter, Patient portal, SMS - Influenza Vaccination, Health Promotion
Not applicableCompletedGeisinger Clinic432252022-09-062022-10-12
Evaluation of Letters Promoting Colorectal Cancer Testing
Letter, Loss Frame and Fear Appeals, Transparency - Cancer Colorectal
Not applicableCompletedGeisinger Clinic146442020-07-242021-09-24
CMO Letter to Reduce Inappropriate Antibiotic Prescribing Winter 2019/2020
Letter - Prescribing, Off-Label
Not applicableCompletedPublic Health England29632019-08-312020-09-29
Trial to Assess Implementation of New Research in a Primary Care Setting (TRAINS)
Letter - General Practice (GP), Primary Care Settings
Not applicableCompletedUniversity of Sheffield13892019-08-012023-05-18
Maine Lung Cancer Coalition: Using CHWs for the Annual Lung Cancer Screening Reminder
Letter, Community Health Worker Phone Call - Lung Cancer
Not applicableCompletedAnne Conners3962019-07-162020-11-30
Behavioral Science and Hepatitis C Screening Outreach
Opt-Out, Letter, Behavioral Economic Messaging - Hepatitis C
Not applicableCompletedUniversity of Pennsylvania214932019-03-152020-12-01
Herd Immunity and Influenza Vaccine Uptake
Letter - Influenza, Human
Not applicableCompletedFinnish Institute for Health and Welfare481252018-10-012025-08-20
Comparing Methods of Recall for Cancer Screening in Primary Care: a Pragmatic Clinical Trial
Letter, Phone call - Early Detection of Cancer, Cancer
Not applicableCompletedUnity Health Toronto52702015-07-012016-10-17
Targeted Letters to Reduce Avoidable Emergency Department Attendances
Letter - Avoidable Emergency Department Attendances
Not applicableUnknownThe Behavioural Insights Team250002015-01-012015-01-08
The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting
Personalized letter, Flyer advertisement, Newspaper press release - Herpes Zoster
Not applicableCompletedUniversity of Tennessee2052008-02-012009-04-23

Conditions studied

Risk Reduction Behavior (3)  ·  Behavior (2)  ·  Communication (2)  ·  Influenza, Human (2)  ·  Breast Neoplasms (1)  ·  Colonic Neoplasms (1)  ·  Health Behavior (1)  ·  Hepatitis C (1)  ·  Herpes Zoster (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)

Sponsors

Geisinger Clinic (3)  ·  Anne Conners (1)  ·  Finnish Institute for Health and Welfare (1)  ·  Public Health England (1)  ·  The Behavioural Insights Team (1)  ·  Unity Health Toronto (1)  ·  University of California, San Francisco (1)  ·  University of Pennsylvania (1)  ·  University of Sheffield (1)  ·  University of Tennessee (1)

Countries

United States (7)  ·  United Kingdom (2)  ·  Canada (1)  ·  Finland (1)

Top investigators

Amir Goren, PhD (2)  ·  Aisha Lofters, MD PhD CCFP (1)  ·  Christopher Chabris, PhD (1)  ·  Cindy T Smith, Pharm.D. (1)  ·  Cornelia Betsch, PhD (1)  ·  Elizabeth Wick, MD (1)  ·  Hanna Nohynek, PhD (1)  ·  Hannah Behrendt, MPhil, BA (1)  ·  Heini Salo, PhD (1)  ·  Lindsay J Ford, Pharm.D. (1)  ·  Nina H Jaber, Pharm.D. (1)  ·  Richard Randolph, Pharm.D. (1)

Results publications

PMID 34006604, PMID 35139082, PMID 36397087, PMID 37997062, PMID 40987739, PMID 41667505

NIH funding

1UG3AG081663-01 (1)